Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Paul Senior who wrote (79016)	1/28/2026 11:49:54 AM
From: E_K_S	Respond to of 79147

I got my ZBH add too at $85.11/share; a very small add (5 shares as I build position) Company already warned earlier this month from their 1/9 presentation. Just said growth was going to be a bit less but still profitable w/ good FCF. UBS has Sell rating w/ $86 price target today

To: Paul Senior who wrote (79016)

2/10/2026 7:54:26 AM

From: E_K_S

Read Replies (1) | Respond to of 79147

RE: Zimmer Biomet Holdings (ZBH) - earnings

Looks our recent Buys are going to pay off on Forward PE. Still at a 50% position and may add at/near $90/share. ZBH offers compelling value at 10.6x forward earnings with a 6.6% FCF yield

------------------------------------------------

Zimmer Biomet (ZBH) Q4 2025 Earnings Summary Quarterly Results (Q4 2025):

Revenue reached $2.244 billion, up 10.9% reported (9.2% constant currency, 5.4% organic) PR Newswire
Adjusted EPS of $2.42, up 4.8% year-over-year PR Newswire
GAAP EPS of $0.70, down 41.7% PR Newswire (impacted by restructuring and acquisition costs)

Full Year 2025 Performance:

Total revenue of $8.232 billion, up 7.2% reported (6.4% constant currency, 3.9% organic) PR Newswire
Adjusted EPS of $8.20, up 2.5% PR Newswire
Free cash flow of $1.172 billion Stock Titan

Segment Performance (Q4):

Knees: 8.6% growth (6.9% constant currency)
Hips: 6.8% growth (4.9% constant currency)
S.E.T.: 20.1% growth (organic 2.9%, boosted by Paragon 28 acquisition)

Key Strategic Moves:

Board approved new $1.5 billion share buyback authorization Stock Titan
$250 million repurchased in Q4 2025 PR Newswire
Transitioning to predominantly direct and specialized U.S. sales organization

ZBH 2026 Valuation Proposition 2026 Guidance:

Adjusted EPS: $8.30-$8.45 Investing.com (midpoint $8.375)
Revenue growth: 2.5%-4.5% reported (2.0%-4.0% constant currency; 1.0%-3.0% organic)

Current Valuation Metrics: Stock Price: $88.65 (as of Feb 9, 2026) Robinhood
Market Cap: $17.7 billion Robinhood

P/E Ratios:

Trailing P/E: 22.25 Robinhood
Forward P/E: 10.53 GuruFocus (based on 2026 guidance)

2026 Forward P/E: $88.65 / $8.375 = 10.6x

Free Cash Flow Analysis:

2025 FCF: $1.172 billion Stock Titan
FCF Yield: $1.172B / $17.7B = 6.6%
Projected 2026 FCF growth expected given operational improvements and lower integration costs

Growth Profile: Expected CAGR (2025-2026):

EPS Growth: $8.20 to $8.375 (midpoint) = 2.1% CAGR
Revenue Growth: 2.5%-4.5% reported = ~3.5% CAGR (midpoint)

Longer-term growth drivers:

New product cycle ("Magnificent 7" launches)
ROSA Knee robotics platform expansion
Paragon 28 foot & ankle integration
U.S. sales reorganization (short-term headwind, long-term benefit)

Valuation Summary:
MetricValueAssessment<tbody]

2026 Forward P/E	10.6x	Attractive vs. peers (discount to sector average PE of 34.55)
FCF Yield	6.6%	Strong cash generation
Expected EPS CAGR	~2%	Modest near-term growth (depressed by sales reorganization)
Expected Revenue CAGR	~3.5%	Below historical but improving post-restructuring
Analyst Price Target	$102.74 average FinancialContent	16% upside from current levels

Investment Considerations: Positives:

Deeply discounted valuation (10.6x forward P/E vs. 34.55x sector average)
Strong FCF generation with 6.6% yield
$1.5B buyback authorization provides support
Innovation cycle accelerating with new products gaining traction

Headwinds:

U.S. sales reorganization tempering 2026 guidance PR Newswire
Integration costs from Paragon 28 and Monogram acquisitions
Modest near-term EPS growth of ~2%

Verdict: ZBH offers compelling value at 10.6x forward earnings with a 6.6% FCF yield. The stock trades at a significant discount to healthcare equipment peers, presenting opportunity for patient investors willing to look through near-term sales reorganization headwinds toward improved execution in 2027+.